Pharmacokinetics and Pharmacodynamics of Human Regular U-500 Insulin (U-500R) Administered via Continuous Subcutaneous Insulin Infusion (CSII) vs. Subcutaneous Injection (SCI) in Adults with Type 2 Diabetes and High Insulin Requirements

Article Authors: Xiaosu Ma, Charles T Benson, Randy Prescilla, Shuyu Zhang, Helle Linnebjerg, Elizabeth S LaBell, Linda A Morrow, Jeffrey A Jackson, Alex Nguyen, Liza L Ilag, Jennal L Johnson, Derek Leishman

Publication Authors:

Xiaosu, M.A.; Prescilla, R.P.; Zhang, S; Linnebjerg, H; Morrow, L; Jackson, J.A.; Johnson, J; Leishman, D
Poster presented at American Diabetes Association (ADA) 78th Scientific Sessions, Orlando, FL. 2018 Jun.

About This Article

Human regular U-500 insulin (U-500R) is approved for subcutaneous (SC) injection in patients with diabetes requiring >200 units/day of insulin. Here, pharmacokinetic and pharmacodynamic (PK/PD) profiles following U-500R administered by continuous subcutaneous insulin infusion (CSII) and SC injection in adults with type 2 diabetes (T2D) on high-dose insulin were studied.

View Now
Pharmacokinetics and Pharmacodynamics of Human Regular U-500 Insulin (U-500R) Administered via Continuous Subcutaneous Insulin Infusion (CSII) vs. Subcutaneous Injection (SCI) in Adults with Type 2 Diabetes and High Insulin Requirements thumbnail